Wall St. Icon: “If you wait on this, it will already be too late”

If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.

Kenneth W. O'Keefe net worth and biography

Kenneth O'Keefe Biography and Net Worth

Director of Jazz Pharmaceuticals

Kenneth W. O’Keefe brings an exceptional business analytics mindset along with corporate development and financial expertise to Jazz’s board. During his 24 year service as the founder of BPOC, LLC, a healthcare private equity firm, Mr. O’Keefe has developed a keen business savvy and provides a diverse perspective to the pharmaceutical space.

Mr. O’Keefe has served as a member of our board of directors since 2004. He served as Managing Director from January 1996 to January 2010 and Chief Executive Officer from January 2010 to January 2018 of BPOC, LLC. Since January 2018, he has served as Founder of and Advisor to BPOC, LLC. He serves on the boards of several privately-held healthcare companies and numerous charitable and civic boards. He received a B.A. from Northwestern University and an M.B.A. from the University of Chicago.

What is Kenneth W. O'Keefe's net worth?: The estimated net worth of Kenneth W. O'Keefe is at least $2.83 million as of March 7th, 2023. Mr. O'Keefe owns 22,889 shares of Jazz Pharmaceuticals stock worth more than $2,832,056 as of December 24th. This net worth estimate does not reflect any other assets that Mr. O'Keefe may own. Learn More about Kenneth W. O'Keefe's net worth.
How do I contact Kenneth W. O'Keefe?: The corporate mailing address for Mr. O'Keefe and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Kenneth W. O'Keefe's contact information.
Has Kenneth W. O'Keefe been buying or selling shares of Jazz Pharmaceuticals?: Kenneth W. O'Keefe has not been actively trading shares of Jazz Pharmaceuticals in the last ninety days. Most recently, Kenneth W. O'keefe sold 2,690 shares of the business's stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $138.39, for a transaction totalling $372,269.10. Following the completion of the sale, the director now directly owns 22,889 shares of the company's stock, valued at $3,167,608.71. Learn More on Kenneth W. O'Keefe's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Kenneth W. O'Keefe Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2023	Sell	2,690	$138.39	$372,269.10	22,889
12/4/2019	Sell	6,750	$147.82	$997,785.00	5,644
11/14/2016	Buy	2,000	$113.84	$227,680.00	12,107

Kenneth W. O'Keefe Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $123.73

$121.19

$124.61

50 Day Range

MA: $119.15

$108.05

$127.74

2 Week Range

Now: $123.73

$99.06

$134.17

Volume

187,949 shs

Average Volume

672,842 shs

Market Capitalization

$7.48 billion

P/E Ratio

17.43

Dividend Yield

N/A

Beta

0.57

Wall St. Icon: “If you wait on this, it will already be too late”

From InvestorPlace | Ad